Preclinical evaluation of pemetrexed in pediatric solid tumors

Pediatric Blood and Cancer

Volumn 57, Issue 7, 2011, Pages 1233-1235

  Norris, Robin E ^a   Rappaport, Eric F ^a   Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Antifol; In vitro; Methotrexate; Pediatric; Pemetrexed

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; METHOTREXATE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; SULFORHODAMINE B; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CHILDHOOD CANCER; CYTOTOXICITY; DRUG SENSITIVITY; EWING SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GLUTAMATES; GUANINE; HUMANS; INHIBITORY CONCENTRATION 50; METHOTREXATE; NEOPLASMS; PEDIATRICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80053904510     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23286     Document Type: Article

References (17)

1. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5: 621-627.
2. Patino-Garcia A, Zalacain M, Marrodan L, et al. Methotrexate in pediatric osteosarcoma: Response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J Pediatr 2009; 154: 688-693.
3. Adamson PC, Balis FM, Miser J, et al. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res 1992; 52: 521-524.
4. Horton TM, Blaney SM, Langevin AM, et al. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: A pediatric oncology group study. Clin Cancer Res 2005; 11: 1884-1889.
5. Estlin EJ, Pinkerton CR, Lewis IJ, et al. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation. Br J Cancer 2001; 84: 11-18.
6. Cohen MH, Johnson JR, Wang YC, et al. FDA drug approval summary: Pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005; 10: 363-368.
7. Hazarika M, White RM, Jr., Booth BP, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005; 11: 982-992.
8. Shih C, Habeck LL, Mendelsohn LG, et al. Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998; 38: 135-152.
9. Norris RE, Adamson PC. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. Cancer Chemother Pharmacol 2010; 65: 1125-1130.
10. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
11. Nilbert M, Saeter G, Elomaa I, et al. Ewing's sarcoma treatment in Scandinavia 1984-1990-Ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. Acta Oncol 1998; 37: 375-378.
12. Munoz A, Madero L, Amaya J, et al. Local control and survival of Ewing's sarcoma in children with radiotherapy and chemotherapy without radical surgery. Acta Oncol 1989; 28: 245-248.
13. Bode U, Erps M, Schiffer D. 42-hour methotrexate infusions as relapse therapy for childhood malignancies: Toxicity and efficacy of 109 infusions. Pediatr Hematol Oncol 1987; 4: 15-24.
14. Balis FM, Gillespie A, Belasco J, et al. Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs 1990; 8: 181-182.
15. Cao S, McGuire JJ, Rustum YM. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: Role of dosing schedule and plasma thymidine. Clin Cancer Res 1999; 5: 1925-1934.
16. Jackman AL, Taylor GA, Calvert AH, et al. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem Pharmacol 1984; 33: 3269-3275.
17. Warwick AB, Malempati S, Krailo M, et al. Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study. ASCO Meeting Abstracts 2010; 28: 9535.